Jake Lesnik, Co-Founder and CEO of DM Therapeutics, joins EisnerAmper's TechTalk host Janina Teoxon to discuss how his gene therapy company developed a novel, non-viral platform designed to improve the efficacy, safety, and accessibility of gene therapies for inherited diseases. In this episode, discover how its non-viral Dark Matter DNA™ technology overcomes the limitations of viral vector-based gene therapies by providing long-lasting therapeutic effects and the capacity to deliver larger, more complex genes. Tune in to learn more about the company’s mission to turn its breakthrough into new medicines and curative therapies that could expand the range of treatable inherited diseases.
EisnerAmper Podcast